Soviet & Russian pharmacology · 1970 – 2026
A working archive of the St. Petersburg peptide school
Half a century ago, a military medical academy in Leningrad started extracting peptides from calf thymus and giving them to soldiers, cosmonauts, and submarine crews. The lab outlasted the Soviet Union. Its founder, Vladimir Khavinson — colonel, gerontologist, the man who ran the programme for forty years — died in January 2024. What he left behind is an inventory of twenty-six compounds, more than seven hundred papers, and one uncomfortable fact: most of the published evidence for these drugs was produced by the people who invented them.
This archive is an attempt to make that corpus legible — what the compounds actually are, who developed them, where the literature is credible and where it isn't, and what was lost when the founder's main manufacturer (Samson-Med, St. Petersburg) stopped producing thymalin in October 2025 and began heading into bankruptcy.
Bioregulators
- Bronchogen A four-amino-acid peptide (Ala-Glu-Asp-Leu) developed for bronchial indications. One published paper (PMID 22117547), no PubChem entry, and essentially no Western literature.
- Cardialin Polypeptide fraction from porcine cardiac tissue, registered in Russia for cardiac dystrophy and post-infarct recovery. Distinct from the synthetic Cardiogen (AEDR tetrapeptide) — same programme, different chemistry.
- Cardiogen A four-amino-acid peptide (Ala-Glu-Asp-Arg) developed for cardiac indications. CyberLeninka only — no Western database entry and no clinical literature outside the Khavinson group.
- Chonluten A three-amino-acid peptide (Glu-Asp-Gly) — the N-terminal tripeptide of Epitalon — sold in Russia as capsules, sublingual drops, and 20 mg vials. The clearest example of Khavinson-school dietary supplements following directly from peptide characterization work.
- Cortagen A four-amino-acid peptide (Ala-Glu-Asp-Pro) developed as a defined-sequence companion to Cortexin. Published literature only — no Russian clinical registration under this exact name.
- Cortexin Polypeptide fraction from pig-brain cortex, sold in Russia as a nootropic and post-stroke neuroprotector. One of the few Khavinson peptides with measurable Russian clinical adoption outside gerontology.
- Crystagen Crystagen bioregulator peptide (Khavinson school). Limited CyberLeninka record; full source PDFs preserved in the dossier.
- Epitalon Synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly). The Khavinson school's flagship anti-aging claim — said to switch telomerase back on — and the only Khavinson peptide with a near-independent replication (Brunel University London, 2025).
- Epithalamin Pinealgland polypeptide fraction — Khavinson's 1970s predecessor to the defined tetrapeptide Epitalon. Largely replaced in clinical use once the shorter, synthesizable sequence was characterized.
- Livagen A four-amino-acid peptide (Lys-Glu-Asp-Gly) sold in Russia as a hepatoprotective. Thin PubMed footprint; the CyberLeninka record is the deeper source.
- Normoftal Normoftal bioregulator peptide (Khavinson school). Limited primary literature; full source PDFs preserved in the dossier.
- Ovagen Ovagen bioregulator peptide (Khavinson school). Limited primary literature; full source PDFs preserved in the dossier.
- Pancragen A four-amino-acid peptide (Lys-Glu-Asp-Trp, in the KEDW form characterized by Tarnovskaya 2013) developed for pancreatic indications.
- Pinealon A three-amino-acid peptide (Glu-Asp-Arg) sold in Russia as a nootropic. The mechanism literature — actoprotective, cognitive, endocrine — is the most internally consistent in the Khavinson corpus; the human-trial evidence is still thin.
- Pineamine Pineamine bioregulator peptide (Khavinson school). Limited primary literature; full source PDFs preserved in the dossier.
- Prostatilen Polypeptide fraction from bovine prostate — registered in Russia for chronic prostatitis and post-surgical recovery. One of the earliest Khavinson cytomedins to be commercialized and the one with the most consistent Russian clinical use.
- Retinalamin Polypeptide fraction from mammalian retina, registered in Russia for retinal dystrophies and post-surgical retinal recovery.
- Testagen Polypeptide fraction from bovine testicular tissue, used in Russian andrology for low sperm count and age-related androgen decline. Earlier attribution to a defined KEDW tetrapeptide has been retracted in our dossier; this is a tissue extract, not a sequence.
- Thymalin Polypeptide fraction extracted from calf thymus. The school in its original Soviet form: registered in Russia, given to soldiers, now at the centre of a real supply crisis after Samson-Med stopped manufacturing it in October 2025.
- Thymogen A two-amino-acid peptide (Glu-Trp) that is the active fragment of Thymalin, sold separately as an over-the-counter immunomodulator in Russia. Listed here because Western biohacker vendors confuse it with Thymalin — they are not the same thing.
- Vilon A two-amino-acid peptide (Lys-Glu) developed as a thymic immunoregulator and sold over-the-counter in Russia as a senescence-suppressing dietary supplement. Documented at the cellular level, almost not studied clinically.
Actoprotectors
- Ademol Institute of Organic Chemistry, National Academy of Sciences of Ukraine, 1990s. The one actoprotector that did not come out of a Soviet military or space programme — it is a Ukrainian actoprotector, registered as a uterotonic, and now discontinued. PubChem name-trap: the name resolves to hydroflumethiazide, a diuretic.
- Bemitil Antihypoxic 2-ethylthiobenzimidazole, sold as Metaprot and Bemaktor. Distinct from the adamantane actoprotectors — benzimidazole scaffold — and the only compound in the corpus with a B-grade clinical paper behind it. The 122 °F + 300 mg/m³ carbon-monoxide rodent test is its signature experiment.
- Bromantane Ladasten in Russia, Noofemp in the US. Stimulant-without-tachycardia: the original Soviet claim was an anxiolytic activation profile with no abuse liability, and WADA agreed — it is now banned after the 1996 Atlanta positives. Combines synergistically with bemitil under heat-plus-CO stress.
- Chlodantane Single-dose adaptogen of the oestrogen-activity type. Pre-clinical only — no clinical trial record in the corpus.
- Ethomersol Synthetic antioxidant actoprotector in the 3-hydroxypyridine family. Sold in Russia and CIS as Mexidol and related brands, also repurposed as a neuroprotective in cognitive and anxiety indications.
Class dossiers
- Bioregulators (class) Walk into any pharmacy in St. Petersburg and you can buy, over the counter, a calf-thymus extract invented for Soviet soldiers in the 1970s. Down the street, a synthetic four-amino-acid peptide — advertised as a geroprotector — sits on the same shelf. Both come from the same institute, the work of one man who ran it for forty years: Vladimir Khavinson, who died in January 2024. What follows is the catalogue of what he left behind. There are twenty-six compounds in the corpus: the older complex extracts (Thymalin from calf thymus, Epithalamin from bovine pineal, Cortexin from pig-brain cortex, Prostatilen from bovine prostate, Retinalamin from mammalian retina) and the newer short synthetic peptides his group characterised in the 1990s and 2000s (Epitalon, the four-amino version of Thymalin's active fragment; Thymogen, the dipeptide; Pinealon, Pancragen, Cortagen, Livagen, Cardiogen, the rest). The mechanism the school claims — that short peptides bind DNA in the major groove and re-program tissue-specific gene expression — has three pieces of independent-looking evidence (transporter-mediated uptake shown by in-silico docking in 2023, nuclear penetration observed by microscopy in 2011, and a direct NMR-plus-molecular-dynamics binding study of the EDR tripeptide in 2019). The bigger claims — twenty to forty percent rodent lifespan extension, telomere elongation in human cell lines — come almost entirely from Khavinson's own group, in journals most Western readers have never heard of. There is one near-independent replication: Brunel University London ran an Epitalon dose-response on human cell lines in 2025, with positive results and a figure-files-only correction. That is the highest the evidence gets without leaving the building.
- Actoprotectors (class) In 1977 a Soviet pharmacologist named I.S. Morozov coined a word: *actoprotector*. He meant something specific and a little strange — a compound that raises the ceiling on work output under load, without raising the metabolic cost of doing the work. No rise in oxygen consumption. No rise in heat production. No rise in resting heart rate. The body just accomplishes more with the same fuel. It was a doctrine for soldiers, cosmonauts and submarine crews before it was a doctrine for anybody else. The Soviet military wanted operators who could function on less sleep, in more heat, at altitude, for longer — without the metabolic signature of an amphetamine. The reference compound became bemitil (2-ethylthiobenzimidazole, sold as Antihot in Ukraine and Metaprot in Russia); the most interesting is bromantane (Ladasten), an adamantane that behaves like a stimulant without tachycardia or abuse liability, and was consequently banned by WADA after the 1996 Atlanta Olympics. A handful of others — chlodantane, ademol, ethomersol — round out the chemistry, but only bemitil and bromantane are registered for human use today, and only in Russia or the former Soviet states. The deeper story is the experiments: heat-tolerance testing at fifty degrees Celsius and three hundred milligrams per cubic metre of carbon monoxide, originally developed for Soviet nuclear-exercise troop studies, where the bemitil-plus-bromantane combination held for a hundred and sixty-eight minutes in the critical-heat test, while the canonical CNS stimulant sidnocarb failed outright — a hundred and thirteen minutes, twenty-five less than placebo. The whole class turns on that kind of finding.
- Military / state-sponsored (class) The Soviet pharmacology programmes that have no Western analogue are the ones the West did not see. Radioprotectors for nuclear-industry workers. Antidotes for chemical-warfare agents. Blood substitutes for submarines. Adaptogens for spetsnaz in Afghanistan. Each programme was developed inside a closed institute under a closed mandate; the residue that surfaced into the open literature is what survives here. Six institutions dominate the work. The S.M. Kirov Military Medical Academy in Leningrad (now St. Petersburg), where the actoprotector programme was born. The Volgograd Centre for Biologically-Active-Substance Safety, where the adamantane actoprotectors were scaled. The Burnazyan Institute of Biophysics under FMBA, where the radioprotector thread ran through Vasin, Ushakov and Ilyin. The Institute of Theoretical and Experimental Biophysics at Pushchino, where Perftoran — the world's first approved perfluorocarbon blood substitute — was developed by Maevsky and Ivanitsky in the 1980s. The Institute of Toxicology in St. Petersburg, where Petrov, Sofronov and Nechiporenko produced the modern Russian oxime and carbamate antidote line. And GosNIIOKhT — Vol'sk-17, the closed-city nerve-agent institute where Mirzayanov worked on the A-series before he defected and disclosed the programme to Moscow News in 1992. The compounds came out of programmes that were never declassified in full. The clinical-validation populations were never the ones a Western RCT would draw from — they were cosmonauts (IMBP), submarine crews (GNIIiVM), spetsnaz (VMA, FMBA), nuclear-industry workers at Mayak, Chelyabinsk-40, Seversk and Zheleznogorsk, and the Chernobyl liquidators. That is why the dossier includes a 'Voynich' axis as a first-class organising principle: a substantial fraction of what was developed is closed-formula, closed-protocol, and reconstructable only from the residue in the open Russian-language literature.
- Cholinesterase (class) Acetylcholinesterase is the most targetable enzyme in pharmacology. The same active-site gorge can be hit with four different intents, and the Soviet pharmacology institutes developed all four of them in parallel from the 1950s onward. Hit it irreversibly, and you have a nerve agent — tabun, sarin, soman, VX, the A-series. Hit it with an oxime, and you have the antidote — pralidoxime, obidoxime, dipyroxime, HI-6, the Russian carb-oxime. Hit it with a reversible carbamate, and you have a prophylactic — pyridostigmine, aminostigmine, physostigmine, galantamine. Hit it with a reversible inhibitor that crosses the blood-brain barrier, and you have an Alzheimer's drug — tacrine, donepezil, rivastigmine, galantamine again. The same Russian institutes that developed the weapons developed the antidotes and the prophylactics, often in the same building: ВНИХФИ in Moscow isolated galantamine from Caucasian snowdrop in 1951 (Mashkovsky and Kruglikova-Lvova); the Institute of Toxicology in St. Petersburg produced the carb-oxime and aminostigmine line for the FOV-antidote programme in the 1990s; GosNIIOKhT in Vol'sk developed the A-series nerve agents, until Mirzayanov walked out and told the world in 1992. Galantamine — a Soviet 1951 discovery — eventually became a Western Alzheimer's drug (Razadyne, FDA 2001). Rivastigmine, a physostigmine-scaffold carbamate developed at Hebrew University, took the same tactic to the same target and reached FDA approval in 2000. The bridge this dossier draws is: same molecule, four uses, Soviet-to-Western translation under one continuous chemistry.
- Khavinson genealogy (article) The intellectual lineage behind Soviet peptide bioregulator doctrine — six generations of Soviet biology that the St. Petersburg Institute inherited, transformed and rebranded.
- Voynich index (novel category) A new organising axis: not by molecular class, not by programme, but by how much of the development history is publicly reconstructable. Compounds in the High-Voynich band have pre-clinical dossiers and scattered dissertations but no civilian registration; compounds in the Low-Voynich band have full Russian-language literature and often Western clinical development.
What this archive is
Research-only. No dosing, no health claims, no affiliate links. Every compound has a mechanism narrative built from the primary literature — CyberLeninka abstracts where available, PubMed PMID 1:1 outbound links where not — and every claim on a dossier page sits beside a paper. 761 papers, 768 compound-paper links. Grades are deterministic: contradictions, conflicts of interest, and small n are flagged, not papered over. 3 A-grade rows, 14 B-grade, 466 C-grade. 228 papers are COI-flagged — meaning the authors are the same people who developed the compound. We tell you which.
For a paper-by-paper index, see the full evidence table →.